CBMG Stock UPDATES Cellular Biomedicine Group Inc. (CBMG) 22.27

New Post Public Reply Private Reply Replies (0) Message Board

Sep 10, 2014 at 5:42 AM

Cellular Biomedicine Group Inc. (CBMG) 22.27 $CBMG

Cellular Biomedicine Group Launches Clinical Research Study for Cartilage Defect Stem Cell Therapy
GlobeNewswire - Tue Sep 02, 8:58AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) ("CBMG" or the "Company"

, a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced the launch of a study on human adipose derived mesenchymal progenitor cell (haMPC) therapy for Cartilage Defects (CD) resulting from osteoarthritis (OA) or sports injury. Both arthroscopy and the use of magnetic resonance imaging (MRI) will be deployed to further demonstrate the regenerative efficacy of ReJoin on cartilage defects.

Cellular Biomedicine Group to Present at Rodman & Renshaw Annual Global Investment Conference
GlobeNewswire - Wed Aug 27, 8:23AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company"

a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced that Dr. William (Wei) Cao, CEO, will be presenting at the Rodman & Renshaw 16 Annual Global Investment Conference on Tuesday, September 9 at 4:10 P.M. EDT. The conference is being held September 8-10, 2014 at the New York Palace Hotel in New York City. A live audio webcast of the presentation will be available by accessing http://wsw.com/webcast/rrshq24/.

Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) to Ring The NASDAQ Stock Market Closing Bell
GlobeNewswire - Fri Aug 15, 9:00AM CDT
What:

Cellular Biomedicine Group Reports Second Quarter and First Half 2014 Financial Results and Provides Business Highlights
GlobeNewswire - Thu Aug 14, 10:58AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company"

, a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today reported financial results for the three and six months ended June 30, 2014 and provided business highlights including the six-month data from its Phase I/IIa clinical trial for ReJoin treatment for Knee Osteoarthritis (KOA).

Cellular Biomedicine Group Completes Patient Treatment in Phase IIb Clinical Trial for ReJoin(TM) Therapy for Knee Osteoarthritis
GlobeNewswire - Tue Aug 12, 8:02AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company"

today announced that it has treated the final patient in its Phase IIb trial to further evaluate the safety and efficacy of their proprietary adipose-derived mesenchymal precursor cell (haMPC)-based therapy ReJoin for Knee Osteoarthritis (KOA).

Cellular Biomedicine Group to Ring The NASDAQ Stock Market Closing Bell
GlobeNewswire - Mon Aug 11, 7:00AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company"

today announced that the Company will ring The NASDAQ Stock Market Closing Bell on Monday, August 18, 2014 at 4:00 P.M. EDT. A live webcast will be available at https://new.livestream.com/nasdaq/live.

Cellular Biomedicine Group Announces Acquisition of Immune Cell Therapy Technology and U.S. Patent
GlobeNewswire - Mon Aug 04, 8:16AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company"

, a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced reaching an agreement to acquire Agreen Biotech Co. Ltd. China ("AG"

and its founder's U.S. patent for a total cash and equity consideration of $3.28 million in cash, the issuance of 753,522 shares of CBMG common stock and the issuance of 75,000 shares of CBMG restricted stock units.

Cellular Biomedicine Group Announces Discontinuation of Consulting Business Segment
GlobeNewswire - Mon Jun 30, 8:05AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company"

, a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced the discontinuation of the Company's consulting business segment. The consulting business is expected to be classified as discontinued operations, effective July 1, 2014.

Cellular Biomedicine Group Completes Enrollment in Phase IIb Clinical Trial for ReJoin(TM) Therapy for Knee Osteoarthritis
GlobeNewswire - Thu Jun 26, 7:15AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company"

today announced that it has completed the patient enrollment required for its Phase IIb trial to further evaluate the safety and efficacy of their proprietary adipose-derived mesenchymal precursor cell (haMPC)-based therapy ReJoin for Knee Osteoarthritis (KOA).

Cellular Biomedicine Group Announces Closing of $10 Million Private Placement Offering
GlobeNewswire - Fri Jun 20, 8:58AM CDT
Cellular Biomedicine Group, Inc. (Nasdaq:CBMG) (the "Company"

, a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced the closing of a private placement transaction under which it sold an aggregate of 1,492,537 shares (the "Shares"

of the Company's common stock, par value $0.001 per share (the "Common Stock"

, to selected private investors (the "Investors"

at $6.70 per share, for total gross proceeds of approximately $10 Million.

Cellular Biomedicine Group Releases Positive Six-Month Data From Phase I/IIa Clinical Trial for ReJoin(TM) Treatment of Knee Osteoarthritis (KOA)
GlobeNewswire - Thu Jun 19, 7:30AM CDT
Cellular Biomedicine Group, Inc. (Nasdaq:CBMG) today released the six-month follow-up data analysis of its Phase I/IIa clinical trial for its Rejoin(TM) human adipose-derived mesenchymal precursor cell (haMPC) therapy for Knee Osteoarthritis (KOA). The trial, conducted by Shanghai Renji Hospital, tested the safety and efficacy of intra-articular injections of autologous haMPCs in order to reduce inflammation and repair damaged joint cartilage.

Cellular Biomedicine Group Commences Trading of Its Common Stock on The NASDAQ Capital Market
GlobeNewswire - Wed Jun 18, 7:00AM CDT
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company"

, a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, announced today that its common stock commences trading on NASDAQ under the ticker symbol "CBMG" effective today, June 18, 2014.

Cellular Biomedicine Group Approved for Listing on the NASDAQ Capital Market
GlobeNewswire - Mon Jun 16, 7:00AM CDT
Cellular Biomedicine Group Inc. (OTCQB:CBMG) (the "Company"

, a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, announced today that its common stock has been approved for listing on the Nasdaq Capital Market and is expected to commence trading on Nasdaq under the ticker symbol "CBMG" on June 18, 2014. The Company's common stock will continue to trade as "CBMG" on the OTCQB until the market closes on June 17, 2014.

Cellular Biomedicine Group Releases Positive Results From Phase I Clinical Trial for Hepatocellular Carcinoma
GlobeNewswire - Mon Mar 24, 11:53AM CDT
Cellular Biomedicine Group, Inc. (OTCQB:CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, is pleased to announce positive results from its Phase I clinical trial, which evaluated the safety of TC-DC (Tumor Stem Cell Specific Dendritic Cell) therapy for hepatocellular carcinoma (HCC), the most common type of liver cancer.

Cellular Biomedicine Group Launches Development Program for Asthma Stem Cell Therapy
GlobeNewswire - Mon Mar 17, 12:28PM CDT
Cellular Biomedicine Group Inc. (OTCQB:CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced the launch of their pre-clinical study on human adipose derived mesenchymal progenitor cell (haMPC) therapy for asthma. The study will evaluate the safety and efficacy of haMPCs to treat severe asthma.

Cellular Biomedicine Group Announces Updated Results From Phase I/IIa Clinical Trial for ReJoin(TM) Treatment of Knee Osteoarthritis (KOA)
GlobeNewswire - Mon Feb 24, 10:15AM CST
Cellular Biomedicine Group, Inc. (OTCQB:CBMG) today announced updated analysis of its Phase I/IIa clinical trial for human adipose-derived mesenchymal precursor cell (haMPC) therapy for Knee Osteoarthritis (KOA), which tests the safety and efficacy of intra-articular injections of autologous haMPCs in order to reduce inflammation and repair damaged joint cartilage. Completed in Q4 2013, the data shows no serious adverse events (SAE), suggesting ReJoin cell therapy for KOA patients is safe.

Cellular Biomedicine Group to Present at New York Stem Cell Summit
GlobeNewswire - Wed Feb 05, 6:24PM CST
Cellular Biomedicine Group Inc. (OTCQB:CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced that Dr. Wei (William) Cao, Chief Executive Officer, will be presenting at the 9th annual New York Stem Cell Summit. More than 30 of the world's leaders in this rapidly evolving industry will meet on February 18, 2014 at The Convene in New York City to discuss the global stem cell industry outlook and forecast.

Cellular Biomedicine Group Announces Appointment of New Chief Financial Officer and Board Secretary and New Audit Committee Chair
GlobeNewswire - Fri Jan 03, 11:45AM CST
Cellular Biomedicine Group Inc. (OTCQB:CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced the appointment of Bizuo (Tony) Liu as Chief Financial Officer and Board Secretary and the election of Nadir Patel as Independent Director, Chairman of the Audit Committee of the board of directors of CBMG.

Cellular Biomedicine Group Announces Change of Auditor
PR Newswire - Wed Sep 11, 8:28AM CDT
Cellular Biomedicine Group, Inc. (OTCQB: CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced that the Company has engaged BDO USA, LLP ("BDO"

as its independent registered public accounting firm, replacing Tarvaran Askelon & Company ("TAC"

.

Cellular Biomedicine Group Announces Positive Interim Results from Phase I/IIa Clinical Trial for Treatment of Knee Osteoarthritis (KOA)
PR Newswire - Fri Sep 06, 6:00AM CDT
Cellular Biomedicine Group, Inc. (OTCQB: CBMG) today announced the interim results of its Phase I/IIa clinical trial for human adipose-derived mesenchymal precursor cell (haMPC) therapy for Knee Osteoarthritis (KOA), which tests the safety and efficacy of intra-articular injections of autologous (patient's own) haMPCs in order to reduce inflammation and repair damaged joint cartilage. On schedule for completion in Q4 2013, the interim analysis of the trial has preliminarily demonstrated a significant improvement (P<0.05) from the baseline in clinical scores for SF-36, NRS-11, and WOMAC osteoarthritis indices, and no serious adverse events have been reported.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Webull Faces Class Action: Key Details for Investors

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

WHO and RCSI Bahrain Join Forces on Health Initiatives

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Novo's Research Unlocks New Insights into Food Noise

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

YSTUDIO's Pens: A Nod to the Power of Writing

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

AppLovin Legal Woes: A Deep Dive into Investor Claims

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Servier's Data on Tovorafenib Shows Promise in pLGG

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

EZaccessMD Data Breach: Class Action Lawsuit Looms

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...